Figure 7.

miR‐1‐3p/miR‐206 inhibits HGF‐mediated gefitinib resistance in vivo. A‐B, PC‐9/NC, and PC‐9/HGF cells (10⁷) were inoculated subcutaneously into nude mice on day 0. Mice received oral gefitinib (25 mg/kg/d) and/or locally injected miR‐1‐3p/miR‐206 agomirs, starting on day 10. The tumour size was measured every 3 days, and tumour volumes were calculated as described in Materials and Methods. We set three days of stop gefitinib (stop‐GE) interval to confirm the effect of gefitinib and combined treatment. Error bars indicate standard errors of 3 mice. B, macroscopic appearances of tumours harvested on day 25 are shown. GE:gefitinib